Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi®
This decision sets aside the Notice of Compliance (“NOC”) issued by
“We are very pleased by the Canadian Federal Court’s decision, once again, that the data submitted to support FIRDAPSE’s NOC in
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including (i) whether
Mary Coleman Catalyst Pharmaceuticals, Incmcoleman@catalystpharma.com Media Contact David Schull Russo Partners(858) 717-2310 email@example.com
Source: Catalyst Pharmaceuticals, Inc.